IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION

被引：0
|
作者：
Mutlu, Levent [1 ]
Manavella, Diego [1 ]
Bellone, Stefania [1 ]
Santin, Alessandro [1 ]
机构：
[1] Yale Univ, Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP015/#546
引用
收藏
页码：A54 / A54
页数：1
相关论文
共 50 条
  • [21] Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan D.
    Lopez, Salvatore
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    MEDICAL ONCOLOGY, 2017, 34 (05)
  • [22] Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
    Gulden Menderes
    Elena Bonazzoli
    Stefania Bellone
    Jonathan D. Black
    Salvatore Lopez
    Francesca Pettinella
    Alice Masserdotti
    Luca Zammataro
    Babak Litkouhi
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E. Schwartz
    Alessandro D. Santin
    Medical Oncology, 2017, 34
  • [23] Neratinib Shows Efficacy in the Treatment of HER2/Neu Amplified Epithelial Ovarian Carcinoma In Vitro and In Vivo.
    Menderes, Gulden
    Bellone, Stefania
    Black, Jonathan D.
    Lopez, Salvatore
    Bonazzoli, Elena
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Silasi, Dan-Arin
    Litkouhi, Babak
    Ratner, Elena
    Azodi, Masoud
    Schwartz, Peter
    Santin, Alessandro D.
    REPRODUCTIVE SCIENCES, 2017, 24 : 203A - 203A
  • [24] HER2 Expression Impacts Trastuzumab Deruxtecan Efficacy in Breast Cancer
    不详
    CANCER DISCOVERY, 2023, 13 (10) : 2117 - 2117
  • [25] The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis
    Kou, Liqiu
    Chen, Xiu
    Xie, Xiaolu
    Wen, Qinglian
    Li, Jun
    Li, Yaling
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (08) : 722 - 729
  • [26] Overexpression and amplification of HER2/neu in human ovarian cancer
    Lee, P
    Sahin, A
    Rosen, D
    Liu, JS
    MODERN PATHOLOGY, 2003, 16 (01) : 196A - 196A
  • [27] Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study
    Vosoughi, Elham
    Nafissi, Nellie
    Mahadevan, Aditya
    Lee, Seungshin
    Parajuli, Kritisha
    Rijal, Nejina
    Parajuli, Ritesh
    Mehta, Rita S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Overexpression and amplification of HER2/neu in human ovarian cancer
    Lee, P
    Sahin, A
    Rosen, D
    Liu, JS
    LABORATORY INVESTIGATION, 2003, 83 (01) : 196A - 196A
  • [29] Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
    Modi, S.
    Glass, B.
    Prakash, A.
    Taylor-Weiner, A.
    Elliott, H.
    Wapinski, I.
    Sugihara, M.
    Saito, K.
    Kerner, J. Kaplan
    Phillips, R.
    Shibutani, T.
    Honda, K.
    Khosla, A.
    Beck, A. H.
    Cogswell, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S355 - S356
  • [30] Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer
    Rose, Peter G.
    Kelley, Johanna A.
    Feldman, Myra
    Krivanek, Kevin
    JCO PRECISION ONCOLOGY, 2023, 7
12345